Differentiated thyroid carcinoma: what the nonspecialists needs to know

Area of Science:

• Oncology
• Endocrinology
• Nuclear Medicine

Background:

• Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer.
• DTC exhibits significant heterogeneity, necessitating a multidisciplinary team for optimal patient management.
• Advances in DTC knowledge and treatment underscore the need for increased awareness among general physicians.

Purpose of the Study:

• To provide an overview of diagnostic and therapeutic principles in DTC.
• To highlight key aspects of DTC management relevant to generalists.
• To emphasize the importance of risk stratification and personalized treatment strategies.

Main Methods:

• Review of current diagnostic and therapeutic principles for DTC.
• Categorization of DTC into localized, locally persistent/recurrent, or metastatic disease.
• Description of a three-tiered risk stratification system for localized DTC.

Main Results:

• DTC management necessitates a specialized, multidisciplinary team approach.
• Risk stratification is crucial at baseline and should be ongoing.
• Personalized treatment based on risk, disease characteristics, and patient preferences is essential.
• Metastatic, radioactive iodine-refractory DTC is increasingly classified by molecular subtypes for targeted therapies.

Conclusions:

• Effective DTC management requires a coordinated effort from various medical specialists.
• Ongoing risk assessment and personalized treatment plans are fundamental to improving patient outcomes.
• Molecular subtyping offers new therapeutic avenues for refractory metastatic DTC.